The Ministry of Healthcare of Republic of Azerbaijan granted an approval to conduct clinical trials of the combined use of the Sputnik V and the COVID 19 vaccine AstraZeneca in Azerbaijan.
Previously, the Gamaleya National Center, RDIF, AstraZeneca and R-Pharm signed an agreement to cooperate on COVID-19 vaccine development, which was announced in December 2020.
The trial will take place in several countries
The research aims to evaluate the immunogenicity and safety of the Sputnik V and AstraZeneca vaccines combined use, states R-Pharm.
The research program will take place in several countries, enrolling 100 adults aged 18 years and older.
“R-Pharm has been actively working with the Republic of Azerbaijan for several years, we opened a modern production facility here in 2019, later in 2020 we registered two drugs from our anti-Covid portfolio: Artlegia and Coronavir. This pilot study is vital for developing of a new approach to the prevention of COVID-19, moreover the leading scientific and clinical centers of Azerbaijan will be able to make their own important contribution in this direction,” says Alexey Repik, the R-Pharm Chairman of the Board.
Clinical trials will begin by the end of February.
